» Articles » PMID: 7532306

The Structure of Unliganded Reverse Transcriptase from the Human Immunodeficiency Virus Type 1

Overview
Specialty Science
Date 1995 Feb 14
PMID 7532306
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

The crystal structure of the reverse transcriptase (RT) from the type 1 human immunodeficiency virus has been determined at 3.2-A resolution. Comparison with complexes between RT and the polymerase inhibitor Nevirapine [Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. (1992) Science 256, 1783-1790] and between RT and an oligonucleotide [Jacobo-Molina, A., Ding, J., Nanni, R., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H. & Arnold, E. (1993) Proc. Natl. Acad. Sci. USA 90, 6320-6324] reveals changes associated with ligand binding. The enzyme is a heterodimer (p66/p51), with domains labeled "fingers," "thumb," "palm," and "connection" in both subunits, and a ribonuclease H domain in the larger subunit only. The most striking difference between RT and both complex structures is the change in orientation of the p66 thumb (approximately 33 degrees rotation). Smaller shifts relative to the core of the molecule were also found in other domains, including the p66 fingers and palm, which contain the polymerase active site. Within the polymerase catalytic region itself, there are no rearrangements between RT and the RT/DNA complex. In RT/Nevirapine, the drug binds in the p66 palm near the polymerase active site, a region that is well-packed hydrophobic core in the unliganded enzyme. Room for the drug is provided by movement of a small beta-sheet within the palm domain of the Nevirapine complex. The rearrangement within the palm and thumb, as well as domain shifts relative to the enzyme core, may prevent correct placement of the oligonucleotide substrate when the drug is bound.

Citing Articles

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.

Annan A, Raiss N, Lemrabet S, Elomari N, Elmir E, Filali-Maltouf A Int J Immunopathol Pharmacol. 2024; 38:3946320241231465.

PMID: 38296818 PMC: 10832406. DOI: 10.1177/03946320241231465.


Structural and computational studies of HIV-1 RNA.

Levintov L, Vashisth H RNA Biol. 2023; 21(1):1-32.

PMID: 38100535 PMC: 10730233. DOI: 10.1080/15476286.2023.2289709.


Targeting the Structural Maturation Pathway of HIV-1 Reverse Transcriptase.

Kirby T, Gabel S, DeRose E, Perera L, Krahn J, Pedersen L Biomolecules. 2023; 13(11).

PMID: 38002285 PMC: 10669680. DOI: 10.3390/biom13111603.


Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1).

Sher H, Sharif H, Zaheer T, Khan S, Ali A, Javed H BMC Genomics. 2023; 24(1):276.

PMID: 37226084 PMC: 10206567. DOI: 10.1186/s12864-023-09330-4.


Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Troyano-Hernaez P, Reinosa R, Holguin A Front Microbiol. 2022; 13:866705.

PMID: 35910645 PMC: 9330395. DOI: 10.3389/fmicb.2022.866705.


References
1.
Jones T, Zou J, Cowan S, Kjeldgaard M . Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991; 47 ( Pt 2):110-9. DOI: 10.1107/s0108767390010224. View

2.
Tramontano E, Cheng Y . HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol. 1992; 43(6):1371-6. DOI: 10.1016/0006-2952(92)90515-k. View

3.
Kohlstaedt L, Wang J, Friedman J, Rice P, Steitz T . Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992; 256(5065):1783-90. DOI: 10.1126/science.1377403. View

4.
Ding J, Nanni R, Clark Jr A, Lu X, Tantillo C, Williams R . Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90(13):6320-4. PMC: 46920. DOI: 10.1073/pnas.90.13.6320. View

5.
Bacolla A, Shih C, Rose J, Piras G, Warren T, Grygon C . Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem. 1993; 268(22):16571-7. View